Last reviewed · How we verify
Autologous FL vaccine
At a glance
| Generic name | Autologous FL vaccine |
|---|---|
| Sponsor | Icon Genetics GmbH |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB) (PHASE1)
- A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM) (PHASE1)
- Autologous Vaccine for Follicular Lymphoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Autologous FL vaccine CI brief — competitive landscape report
- Autologous FL vaccine updates RSS · CI watch RSS
- Icon Genetics GmbH portfolio CI